stockrow
Friday 6 November 2026
Export NTRB’s income statement to Excel — free account
Nutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025.
- Revenue
- −29.7%
- EPS
- +96.7%
- Free cash flow
- +55.5%
- Total debt
- −46.9%
Quarter to July 2026, against a year earlier
5.57
0.01
−0.18%
Follow NTRB
Alert me
Nutriband Inc. (NTRB) P/E ratio
Nutriband Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Apr 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Oct 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNOV MediciNova, Inc. compare | n/m |
| CNXU Conexeu Sciences Inc. compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| NTRB Nutriband Inc. | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| COYA Coya Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)